BioSpecifics Technologies Corp

BioSpecifics Technologies — Investor Presentation (November 2014)

27 slides from BioSpecifics Technologies's investor presentation, Nov 4, 2014

  1. Slide 1: Innovators in the development & commercialization of injectable collagenase

    ° \4 Innovators in the development & commercialization of ‘INJECTABLE COLLAGENASE i, . BioSpecifics November 2014

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements This presentation includes “forward-looking statements” within the meaning of, and made pursuant to the safe harbor provisions of, the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are “forward-looking statements”

  3. Slide 3: Corporate Overview

    Corporate Overview BioSpecifics is a profitable, commercial-stage biopharma company maximizing the potential of collagenase clostridium histolyticum or CCH (XIAFLEX®) for multiple commercial and clinical indications XIAFLEX is marketed for two indications in the U.S. by strategic partner, Auxilium P

  4. Slide 4: Vast Therapeutic Potential of CCH

    Vast Therapeutic Potential of CCH CCH provides a first-in-class, minimally invasive nonsurgical treatment option for conditions and diseases caused by collagen accumulation where current treatment options are limited BioSpecifics has positive results in 12 indications: Dupuytren’s contracture’ Froze

  5. Slide 5: Marketed Indications for XIAFLEX

    Marketed Indications for XIAFLEX Marketed Dupuytren’s Approval in Japan expected in mid-2015 Contracture Peyronie’s Approval in the EU expected as early as late 1Q15 Disease Source: Auxilium Pharmaceuticals, Inc.

  6. Slide 6: Commercial Success for XIAFLEX

    Commercial Success for XIAFLEX Impressive Growth In Both Indications Total XIAFLEX revenues up 119% in 3Q14 over 3Q13 XIAFLEX U.S. net revenues for both indications were $34.6M over $15.9M in 3Q13, a 118% increase International revenues increased to $4.0M in 3Q14, a 135% increase U.S. XIAFLEX revenu

  7. Slide 7: XIAFLEX for Dupuytren's Contracture

    XIAFLEX for Dupuytren’s Contracture Formation of a collagen cord in the hand causing one or Definition and more fingers to contract toward the palm Key Complications Limits range of motion of the fingers often resulting in physical disability and impaired quality of life bli ant od Also approved in

  8. Slide 8: XIAFLEX Label Expansion

    XIAFLEX Label Expansion sBLA Approved in October 2014 Expanded label allows for treatment of up to two Dupuytren’s contracture joints in the same hand during a single office visit SDI Health LLC estimates 35 to 40% of annual Dupuytren’s contracture surgeries in U.S. are performed to treat two or mor

  9. Slide 9: Dupuytren's Contracture Commercial Opportunity

    Dupuytren’s Contracture Commercial Opportunity 300K patients diagnosed annually Focus on Consistent USS. Sales Growth 32% market share YTD among all procedures 5,863 vials sold in 3Q14, a 16% increase over 3Q13 Good sales momentum by Sobi within European markets Asahi Kasei submitted regulatory appl

  10. Slide 10: XIAFLEX for Peyronie's Disease

    XIAFLEX for Peyronie’s Disease Definition & Key Complications First and Only FDA- Approved PD Treatment Pre-treatment: Excess of inelastic collagen causing penile curvature; penis can bend at 90° angle during erection in severe cases Pain with erection, penile shortening, indentations, erectile dysf

  11. Slide 11: Peyronie's Disease Commercial Opportunity

    Peyronie’s Disease Commercial Opportunity U.S. Market Opportunity Focus on Patient Access and Market Expansion *Source: Auxilium Pharmaceuticals, Inc. 95K patients* diagnosed in 2013 but believed to be underdiagnosed Up to eight injections (four treatment cycles of two injections) in-office Auxilium

  12. Slide 12: Commercial Progress

    Commercial Progress Focused, disciplined initial product rollout 5,000-6,500 patients receive invasive treatment for Peyronie’s disease each year (plication, grafting, prosthesis surgery or verapamil injections) ~400 urologists account for 90% of PD surgeries REMS certification of urologists 1,450**

  13. Slide 13: Commercial Progress (Cont.)

    Commercial Progress (Cont.) Reimbursement approval by payers (Auxilium Advantage) All eight Medicare beneficiaries confirmed coverage at policy level; 29 major commercial health plans have approved patients for treatment Listed as 'medically necessary’ in Clinical Policy Bulletin, when administered

  14. Slide 14: XIAFLEX Pipeline Programs

    XIAFLEX Pipeline Programs a Top-line data in 1Q15 Pn (eins Auxilium opt-in decision in 4Q14 Lipoma * Human Complete enrollment in Phase 2 in 1Q15 Lipoma Cellulite Initiation of Phase 2b in 2Q15 *Uterine Onaainal Fibroids ssid *BioSpecifics-managed development program

  15. Slide 15: CCH for Canine and Human Lipomas

    CCH for Canine and Human Lipomas BioSpecifics-Managed Programs Encapsulated deposits of benign fatty tumors; detected as bulges Definition and under the skin that occur in both humans and dogs Key Complications Can cause seriously restrict motion in older dogs No FDA-approved pharmaceutical therapie

  16. Slide 16: Encouraging Placebo-Controlled Phase CCH Trial in Canines

    Chien-804: Encouraging Placebo- Controlled, Phase 2 CCH Trial in Canines Randomized trial conducted in canines with benign subcutaneous lipomas. Study did not meet primary endpoint but demonstrated benefit in secondary measures: Responder analysis: » Visible surface area as measured by caliper decre

  17. Slide 17: Positive Phase Clinical Trial Results in Humans

    Positive Phase 2 Clinical Trial Results in Humans Open label, dose escalation Phase 2 trial for humans with benign subcutaneous lipomas showed: Statistically significant (p<0.0001) reduction in primary endpoint of visible surface area of lipoma as measured by caliper, combining all patients Patients

  18. Slide 18: CCH for Uterine Fibroids

    CCH for Uterine Fibroids New Study Results Reported in October 2014 Benign tumors Definition & Pain, decreased fertility, Key Complications miscarriage, heavy menstrual bleeding and frequent urination Primary indication for a aa Potential to be . 025 050 1.00 200 hysterectomy in U.S., accounting Col

  19. Slide 19: CCH for Frozen Shoulder Syndrome

    CCH for Frozen Shoulder Syndrome Top-line Data from Phase 2b Study Expected in 1Q Inflammation and thickening of Definition and shoulder capsule due to collagen Key Complications accumulation Limits range of motion of shoulder Common available treatment noes to eS option is manipulation inly Approve

  20. Slide 20: Statistically Significant CCH Dose Response in Phase 2a Study

    Statistically Significant CCH Dose Response in Phase 2a Study 60 + 1 Statistically significant improvements in P<0.05 Comparis © Forward Flexion both the 0.58 mg(1mL) and 0.58 50 i to Exorcise Cohort} chiar Abduction mg(2mL) cohorts over baseline scores ©) External Rotation vs. the exercise-only gro

  21. Slide 21: CCH for Cellulite

    CCH for Cellulite Positive Phase 2a Top-line Results Reported in 3Q14 Definition Significant Market Opportunity as First Nonsurgical Therapy Top-line Results Reported from Phase 2a Study in 3Q14 Source of data: Auxilium Pharmaceuticals, Inc. Skin dimpling as a result of collagen fibrous septae held

  22. Slide 22: CCH for Cellulite

    CCH for Cellulite Initiation of Phase 2b Study Expected in 2Q15 Top-line Data from Phase 2a Study Mid and high level CCH doses demonstrated statistically significantimprovementin cellulite across all endpoints 68% of mid and high dose groups reported being “Satisfied” or “Very Satisfied” with treatm

  23. Slide 23: Auxilium Partnership for Development and Commercialization of CCH

    Auxilium Partnership for Development and Commercialization of CCH >$45.1M Received Over $45M total received in licensing, sublicensing, milestone, COGS, from Auxilium and royalty payments as of June 30, 2014 Low double digit royalties as % of net sales by Auxilium Additional mark-up on COGS Modest m

  24. Slide 24: Corporate Highlights

    Corporate Highlights Vast opportunity for growth in revenues from XIAFLEX sales and approval of CCH in new indications » Strong Intellectual Property Portfolio Long-term patent protection for injectable collagenase: » Dupuytren’s Contracture: XIAFLEX has Orphan Drug protection in U.S. until 2017; Dr

  25. Slide 25: Consistently Profitable Annually

    Consistently Profitable Annually 2Q14 Financial Highlights For the quarter For the year ended ended 06/30/14 12/31/13 (unaudited) (unaudited) Cash and equivalents, short term investments $ 16,633,708 $ 12,591,825 Income Statement Revenues $ 2,652,505, $ 14,467,240 Other income 7,352 26,202 Costs and

  26. Slide 26: Anticipated Upcoming Milestones

    Anticipated Upcoming Milestones Steady Momentum in BioSpecifics-Managed Indications Upcoming Milestones *Human Lipomas Ocomplete enrollment in Phase 2 placebo-controlled opt-in trial in 1Q15 aoaat rae (120 day opt-in period for Auxilium to license rights ends in 4Q14 ee ed Q Ongoing pre-clinical stu

  27. Slide 27: Innovators in the development & commercialization of injectable collagenase

    Innovators in the development & commercializationof | Qs ECTABLE = t- COLLAGEN Gail B ioSpecifics November 2014 TECHNOLOGIES CORP.

Biospecifics Technologies — Investor Presentation (November 2014) on 6ix